Enkephalins

Met-enkephalin (573.7 Da) and leu-enkephalin (555.6 Da) were the first endogenous opioids identified, cleaved from proenkephalin and prodynorphin. Both prefer the delta opioid receptor but also engage mu, producing analgesia, anxiolysis and reward modulation. Their defining problem is stability: neprilysin (enkephalinase) and aminopeptidase N chew them up within a couple of minutes, so injecting enkephalin is close to pointless as a therapy. That is precisely why the pharmacology went a different route — dual enkephalinase inhibitors such as PL-37 and opiorphin-derived compounds raise endogenous enkephalin tone at the site of release rather than flooding the whole system, which is a far more elegant analgesic strategy and one that keeps resurfacing in development. Separately, met-enkephalin has a second identity as opioid growth factor, acting on a nuclear OGF receptor to slow cell proliferation; that is the pathway low-dose naltrexone is claimed to upregulate, and it drove small oncology trials rather than pain trials.

Targets: Delta opioid receptor (OPRD1), Mu opioid receptor (OPRM1), Opioid growth factor receptor (OGFr), Neprilysin and aminopeptidase N (as the drug-development target)

• · Injecting enkephalin subcutaneously does not produce a useful systemic effect because it is degraded before it distributes. Anyone selling enkephalin for self-injection is selling a peptide that its own enzymes will destroy in about two minutes.
• · Small investigator-led trials in advanced pancreatic cancer infused met-enkephalin as opioid growth factor on a weight-based weekly schedule. The exact dose reported varies between publications, so no specific figure is given here rather than risk quoting the wrong one. This was oncology work, not analgesia.

Work out your exact syringe units →

• uncommonTransient sedation or dizziness with high systemic exposure— Rarely reached given the degradation rate.
• uncommonNausea
• uncommonHistamine-type flushing on rapid IV administration
• rareSeizure activity at very high delta agonist exposure in animals— A known class effect of potent delta agonists in preclinical work, not observed at physiological levels.

• There is no meaningful contraindication list because there is no meaningful human dosing route. The honest position is that direct enkephalin administration does not work well enough to have a risk profile.
• Combining with full mu agonists offers nothing and confounds any opioid dose assessment.

• redundantdalargin — Dalargin is a stabilised leu-enkephalin analogue built specifically to solve the degradation problem; it is what you would use instead of enkephalin, not alongside it.
• cautiondermorphin — Overlapping opioid tone with a far more potent and dangerous agonist.
• redundantendomorphin-1-and-2 — Both are endogenous opioid peptides with the same fatal flaw — near-instant enzymatic degradation.

• · No routine monitoring exists. In any research use the relevant measures are sedation, respiratory rate and analgesic response.

Endogenous peptides sold as research chemicals; not approved as drugs anywhere. Not scheduled, since they have no practical abuse route.

• Hughes et al. 1975, Nature — identification of two related pentapeptides with opiate agonist activity (preclinical)
• Roques et al., dual enkephalinase inhibitors as an alternative to exogenous opioids (review)
• Zagon and McLaughlin, opioid growth factor and the OGF receptor axis (review)

The enkephalins are where opioid pharmacology started making sense, and they are also the cleanest example in the whole field of a molecule that is biologically central and pharmaceutically useless. Hughes and Kosterlitz identified them in 1975 as the endogenous ligands the newly discovered opiate receptors must have evolved for, and the receptor biology has not been seriously disputed since: both pentapeptides prefer the delta opioid receptor (OPRD1) with meaningful mu activity, both are Gi/Go-coupled, and the downstream story is standard — adenylyl cyclase inhibition, GIRK potassium channel opening, presynaptic N-type calcium channel closure. Delta receptor activation in particular carries an anxiolytic and antidepressant signature distinct from mu-mediated analgesia and reward, which is why delta agonism has been chased repeatedly as a mood target. Physiologically, enkephalins are released on demand, act locally within a few micrometres of the release site, and are destroyed almost immediately. That is not a design flaw; it is the design. A neurotransmitter that persists systemically would be a hormone, and opioid tone is deliberately not a hormonal system. Which is exactly why exogenous enkephalin fails: you cannot recreate an on-demand, spatially restricted, self-terminating signal by injecting the ligand into a vein. The pharmacologically intelligent response, worked out largely by Roques and colleagues, is to inhibit the enzymes instead. Dual enkephalinase inhibitors block neprilysin and aminopeptidase N simultaneously, which raises enkephalin concentration only where enkephalin is already being released — at active synapses, in response to actual noxious input. That produces analgesia with markedly less tolerance, no respiratory depression and no reward in animal models, because you are amplifying a physiological signal rather than flooding every opioid receptor in the body. PL-37 and opiorphin-derived compounds are the clinical expression of that idea, and the approach keeps resurfacing because the logic is sound even though nothing has reached approval. Separately and confusingly, met-enkephalin has a second identity as opioid growth factor, acting not at a classical GPCR but at a nuclear-associated OGF receptor to slow cell proliferation by upregulating p16 and p21 cyclin-dependent kinase inhibitors. That is the pathway low-dose naltrexone is claimed to work through — intermittent receptor blockade producing compensatory upregulation of OGF and OGFr — and it drove small oncology trials rather than pain trials. Whether that story is real at the doses people use is a separate question from whether the receptor exists.

The failure here is upstream of dosing: people buy enkephalin as an injectable peptide and it cannot work, no matter how it is dosed, reconstituted or timed. A subcutaneous injection of met-enkephalin is destroyed by tissue peptidases before it distributes, and what does reach the circulation has a one-to-three-minute half-life and cannot cross the blood-brain barrier anyway. There is no dose that fixes this, because the problem is enzymatic and first-order — doubling the dose doubles the substrate for an enzyme system that is nowhere near saturated. The second failure is handling: met-enkephalin oxidises at its methionine within hours in solution, so even the material in the vial degrades faster than most peptides, and repeated freeze-thaw cycles visibly reduce activity. Fresh preparation is standard in research for exactly this reason. The third is interpretive — people report effects from injected enkephalin and attribute them to opioid pharmacology, when the plausible candidates are injection-site histamine release from a cationic peptide, or expectation. The fourth is conflating the two identities: met-enkephalin as an opioid neurotransmitter and met-enkephalin as opioid growth factor are the same molecule doing entirely different things at entirely different receptors, and the small human trials that exist are oncology trials using the OGF framing, not analgesia trials. Quoting oncology infusion protocols as evidence that enkephalin relieves pain is a category error that appears regularly.

• Delta opioid receptor (OPRD1) — Preferential over mu, with the delta selectivity of leu-enkephalin somewhat greater than met-enkephalin's. Specific Ki values are in the classical literature but I did not resolve a primary source in this session, so no figure is asserted.

  Gi/Go coupling: adenylyl cyclase inhibition, GIRK opening, presynaptic calcium channel closure. Delta activation carries a distinctive anxiolytic and antidepressant-like signature in animal models alongside spinal analgesia.

• Mu opioid receptor (OPRM1) — Meaningful but lower than at delta.

  Contributes to analgesia and to reward modulation. This is the arm that overlaps with conventional opioid pharmacology, and it is why raising enkephalin tone produces genuine analgesia rather than just mood effects.

• Neprilysin (neutral endopeptidase) and aminopeptidase N — Enkephalins are the substrate, not the ligand. These enzymes are the actual drug target that the field converged on.

  Inhibiting both simultaneously raises endogenous enkephalin concentration at active synapses only. In animal models this produces analgesia with much less tolerance and no respiratory depression than an exogenous agonist. This — not injected enkephalin — is the viable version of enkephalin pharmacology.

• Opioid growth factor receptor (OGFr) — Met-enkephalin acting as opioid growth factor. Not a classical GPCR — a nuclear-associated receptor.

  Inhibition of cell proliferation via upregulation of p16 and p21 cyclin-dependent kinase inhibitors. The claimed mechanism of low-dose naltrexone, and the basis of small investigator-led oncology trials in advanced pancreatic cancer. Nothing to do with analgesia.

Immediate and immediately over. Any effect from a systemic enkephalin dose would begin within seconds and be finished within a few minutes, because the molecule is gone. This is the single fact that governs the entire class: there is no sustained effect to describe, and any protocol promising one is describing something other than pharmacology. The enkephalinase-inhibitor approach behaves completely differently — it produces a sustained elevation in endogenous enkephalin tone lasting as long as the enzyme stays inhibited — but that is a different drug class, not a different way of dosing enkephalin.

There is nothing coherent to stack with injected enkephalin because injected enkephalin does not produce a systemic effect to build on. The genuinely useful notes are about what to use instead. Dalargin is a stabilised leu-enkephalin analogue built specifically to solve the degradation problem — it is what you would use in place of enkephalin, not alongside it, and the same logic applies to any protease-resistant analogue. Enkephalinase inhibition, if you can get a compound that does it, is the mechanistically correct approach and is incompatible in principle with flooding the system with exogenous agonist: the whole point of raising endogenous tone is spatial and temporal selectivity, which an exogenous agonist destroys. Combining enkephalin with a full mu agonist such as dermorphin adds nothing and makes it impossible to attribute any effect. Combining it with the endomorphins is combining two peptides with the identical fatal flaw. And a note on low-dose naltrexone, since it is the practical route by which most people interact with this pharmacology: LDN and any opioid agonist are directly antagonistic, and running both is self-cancelling in a way that people who take LDN alongside opioid pain medication frequently discover the hard way.

The enkephalins are the most important molecules in this class and the least usable, and holding both facts at once is the point. Scientifically they sit at the origin of everything else on this page: the Tyr1 pharmacophore they defined is the same one in dermorphin, DALDA and the endomorphins, and every one of those molecules is an attempt to fix the enkephalins' single defect. Dermorphin fixed it with D-Ala2 and became too potent to use safely. DALDA fixed it with D-Arg2 and a +3 charge and became too peripheral to be analgesic. The endomorphins are naturally more mu-selective but share the same degradation problem. Dalargin stabilised the leu-enkephalin backbone directly. And the enkephalinase inhibitors abandoned the molecule entirely and went after the enzymes, which is probably the correct answer and is still, fifty years after Hughes and Kosterlitz, not an approved drug. Against ziconotide, difelikefalin or the CGRP class — all of which have phase 3 data and labels — the enkephalins have zero evidence of useful human analgesia by any administered route. The register difference matters: this is textbook-solid physiology and unusable pharmacology, and the site should never let the first fact borrow credibility for the second.

Deliberately not priced. Enkephalins are sold as research reagents and there is no dosing protocol that produces a systemic effect, so a monthly cost figure would imply a working use pattern that does not exist. Any money spent on injectable enkephalin is buying a peptide that its own enzymes destroy in about two minutes.

• ?No Ki values at delta or mu are asserted; the classical binding data exists but I did not resolve a primary source in this session.
• ?The exact dose and schedule used in the small met-enkephalin (opioid growth factor) oncology trials in advanced pancreatic cancer varies between publications and is not stated here rather than risk quoting the wrong figure.
• ?The claim that low-dose naltrexone works via compensatory upregulation of OGF and OGFr is a mechanistic hypothesis, not an established finding in humans, and the human evidence for LDN in any indication remains weak.
• ?The one-to-three-minute plasma half-life is the consensus figure across the literature; I did not resolve a primary pharmacokinetic source for it in this session.
• ?Whether enkephalins have any meaningful peripheral analgesic action at injection sites, as distinct from systemic action, has not been properly studied and is the one place where a subcutaneous dose could theoretically do something.
• ?Molecular weights were verified via PubChem; the Core record leaves molecularWeightDa null, and it could reasonably be populated with 573.7 for met-enkephalin and 555.6 for leu-enkephalin.

• Identification of two related pentapeptides from the brain with potent opiate agonist activity Hughes J, Smith TW, Kosterlitz HW, et al., Nature, 1975 · PMID 1207728

  The founding paper of endogenous opioid pharmacology. Met-enkephalin and leu-enkephalin identified as the ligands the opiate receptors evolved for. Everything downstream — endorphins, dynorphins, endomorphins, the entire opioid peptide field — starts here.